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SObjective: The incidence of esophageal adenocarcinoma is rapidly increasing in the western population.
Despite aggressive treatment, survival after esophagectomy is suboptimal. The main objective of the present
studywas to evaluate the gene expression profiles in esophageal adenocarcinoma and determine their association
with survival after resection.
Methods: We conducted a prospective National Institutes of Health/National Cancer Institute funded study to
evaluate the prognostic significance of gene expression in patients with esophageal adenocarcinoma undergoing
esophagectomy. Gene expression in tumor tissue was analyzed using high-throughput oligonucleotide arrays.
The association of gene expression and overall survival was analyzed using the tail-strength statistic and Cox
regression analysis. Gene signatures were constructed with semisupervised methods using principal compo-
nents. A cross-validated risk score was devised by conducting 10-fold cross-validation, 100 times.
Results: We evaluated the gene expression in 64 patients with esophageal adenocarcinoma who underwent
esophagectomy. The median overall survival was 27 months (95% confidence interval 22 to not reached). After
filtering, 10,214 probe sets were used for survival analysis. The tail-strength statistic for these probe sets (0.318)
indicated a significant association with overall survival. Patients were classified into high- and low-risk groups,
according to the gene signature. High-risk patients had a predicted median survival of 19 months, but the median
was not reached for the low-risk group (P<.05). On multivariate analysis, the gene signature was independently
associated with survival (hazard ratio, 2.22; P ¼ .04).
Conclusions: Global gene expression levels were significantly associated with overall survival after esophagec-
tomy. Furthermore, individual genes could be successfully combined into a strongly predictive, internally
cross-validated gene signature. If validated further, these results could help direct additional clinical trials
of neoadjuvant and adjuvant therapies for esophageal adenocarcinoma. (J Thorac Cardiovasc Surg
2013;145:505-13)The incidence of esophageal cancer has been dramatically
increasing during the past 3 decades.1,2 In the United
States and the western population, this profound increase
has resulted from an increase in the incidence of
adenocarcinoma of the esophagus. The incidence of
esophageal adenocarcinoma (EAC) now exceeds that of
squamous cell carcinoma in the United States and the
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The Journal of Thoracic and Carelated to gastroesophageal reflux disease, obesity, and
Barrett’s esophagus (BE), which are the dominant risk
factors.2 In the United States, the estimated incidence of
esophageal cancer was more than 16,000 cases in 2009.1
The overall outcome after the diagnosis of esophageal
cancer is suboptimal, with a 5-year survival rate of 15%
to 25%, although an improvement in survival, associated
with early-stage disease, was seen in recent surgical series.3
Accurate staging before treatment is important and facil-
itates the selection of appropriate treatment strategies. De-
spite improvements, however, the current clinical staging
modalities have not proved very accurate.4-6 A better
understanding of the biologic behavior of the tumor will aid
in the selection of appropriate therapies, with the potential
to improve the outcomes of those with esophageal cancer.
The analysis of the gene expression profiles associated with
different outcomes could potentially be useful for the
careful selection of therapies and could also aid in tailoring
treatment to the individual patient.7,8
Although the expression of single genes or specific path-
ways have been studied in the pathophysiology of cancer,9 it
is clear that the pathogenesis and progression of cancer is
a complex process involving many genes and pathways.rdiovascular Surgery c Volume 145, Number 2 505
Abbreviations and Acronyms
BE ¼ Barrett’s esophagus
CI ¼ confidence interval
EAC ¼ esophageal adenocarcinoma
HR ¼ hazard ratio
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SGene expression profiling with microarrays is a powerful
and promising modality for evaluating the expression of a
large number of genes and evaluating changes in genome-
wide expression.8 The gene expression pattern of the pri-
mary tumor has been shown to predict the outcome for
several malignancies, including lung cancer, head and
neck cancer, and breast cancer.10-13 Several studies have
explored gene expression in squamous cell cancer of the
esophagus, and differential gene expression between
esophageal cancer cell types has also been evaluated.
However, currently, studies evaluating the prognostic
implications of genome-wide changes in the gene expres-
sion for EAC are limited.14-19
Our main hypothesis was that the gene expression pat-
terns observed in EACwould be associated with survival af-
ter surgical resection.We hypothesized that a set of genes or
gene profile would be predictive of survival after surgical
resection in patients with EAC. The main objective of the
present study was, therefore, to evaluate the gene expres-
sion profiles of EAC, identify individual genes associated
with outcome, and build a gene expression signature to
identify high- and low-risk patients.
METHODS
Patients
We conducted a prospectiveNational Institutes of Health, National Can-
cer Institute–funded study to evaluate the prognostic significance of gene
expression profiles in EAC. The institutional review boards at the Univer-
sity of Pittsburgh and other participating institutions approved the study
protocol. All patients enrolled in the present study provided informed con-
sent. Tumor tissues were prospectively collected from eligible patients who
had provided informed consent prior to undergoing esophagectomy for
EAC of the esophagus at the University of Pittsburgh Medical Center
from 2002 to 2006. The present study involved prospective patient
consent, tissue and data collection, and correlative analysis with gene
expression. More details on the tissue collection and processing and gene
expression analysis are provided under individual subheadings in this sec-
tion. Patient inclusion criteria included histologically proven adenocarci-
noma, complete surgical resection with negative margins, and the
absence of induction therapy. Patients were excluded if they were found
to have distant metastatic disease on surgical exploration or if they died
within 30 days of the operation date. Computed tomography, endoscopic
ultrasonography, minimally invasive staging, and positron emission tomog-
raphy were used for staging. We have previously shown that minimally in-
vasive staging is more accurate than positron emission tomography for the
detection of distant metastasis.4 Patients underwent disease staging with
computed tomography (64/64; 100%), endoscopic ultrasonography (47/
64; 73.44%), and minimally invasive staging (52/64; 81.25%). Minimally
invasive staging and/or positron emission tomography was performed in 57
patients (57/64; 89.06%). The surgical approach was at the discretion of506 The Journal of Thoracic and Cardiovascular Surgthe operating surgeon. Our primary technique for esophagectomy has
been previously detailed.20
Tissue Handling and RNA Isolation
Esophageal tumor tissue was obtained during surgical resection and im-
mediately snap frozen at 80C until additional analysis. All tissues were
mounted in optimal cutting temperature compound before sectioning on
the cryostat. The first and last sections were mounted on slides for patho-
logic evaluation and intervening sections (20-30 sections; 5 mM each)
were cut into RNA lysis buffer (Stratagene, La Jolla, Calif). All tissues
were evaluated by a pathologist to verify adequate tumor representation
in the sample before additional analysis. Total RNA was extracted using
the Stratagene RNA Isolation Kit according to the manufacturer’s protocol.
RNA quality and purity were assessed by capillary electrophoresis using an
Agilent Bioanalyzer (Agilent, Santa Clara, Calif) and ultraviolet spectro-
photometer (Nanodrop, Wilmington, Del).
Microarray Hybridization and Raw Data Processing
Total RNA (1 mg) was labeled with biotin using a single-round in vitro
transcription reaction and hybridized to Affymetrix U133 Plus 2.0 gene ex-
pression arrays in accordance with the manufacturer’s recommended pro-
tocols (Affymetrix, Santa Clara, Calif). Processed microarrays were
scanned using the GeneChip Scanner 7G, and the raw image files were
checked visually and then processed using the Affymetrix GeneChip oper-
ating software package to obtain individual probe hybridization intensities.
The guidelines for acceptable labeling and hybridization quality, as sug-
gested by the manufacturer, were met for all arrays. Raw data were pro-
cessed using the Partek Genomic Suite (Partek, St. Louis, Mo) using the
gene chip robust multiarray averaging approach to provide normalized
expression data for each probe set on the arrays.
Gene Expression Analysis
Microarray probe set data were filtered to exclude probe sets without
a corresponding gene symbol and subsequently filtered to exclude the
probe sets with low variance across the patients defined as less than the
75th percentile of probe set variance. The probe sets that passed the filter
but mapped to the same gene symbol were averaged. An overall assessment
of the univariate significance of the set of filtered probe sets was checked
using the tail-strength statistic. The semisupervised method of Bair and
Tibshirani21 was applied to the genes. Twenty thresholds, defined by the
minimum absolute standardized Cox regression coefficients (Wald scores),
were evaluated for significance with 10-fold cross-validation. The thresh-
old of 2.0 was then selected, corresponding to 59 genes. For empirical val-
idation of the 59 genes, an unsupervised hierarchical classification was
conducted, and the patients were divided into 2 groups. A set of 3 principal
components was used to predict a risk score, which was used for the sur-
vival analysis. A cross-validated risk score was devised by conducting
10-fold cross-validation 100 times and averaging the patient risk scores
across the 100 repetitions. We performed pathway analysis using the Inge-
nuity Systems and the MetaCore program.
Survival Analysis
The primary end point of the study was overall survival. Kaplan-Meier
plots were constructed for estimation of overall survival, for the entire co-
hort and for subsets according to risk group. Risk groups were formed by
stratifying the gene expression risk scores at the median to form high-
and low-risk categories. The log-rank test was used to analyze the differ-
ences between the 2 groups. A multivariate proportional hazards model
was applied to adjust the gene signature risk classification score for patho-
logic Tand N stage. Staging was performed according to the 6th and the 7th
edition of the AJCC Cancer Staging Manual. Adequacy of the proportional
hazards assumptions was checked by the correlation between the time and
Schoenfeld residuals.22ery c February 2013
TABLE 1. Patient characteristics
Characteristic Value
Gender (n)
Male 54
Female 10
Age (y)
Median 68
Range 43-88
Histologic type: adenocarcinoma (%) 100
Final pathologic stage (n)
T stage
T1 25
T1a 5
T1b 20
T2 8
T3 30
T4 1
N stage
AJCC 6th edition
N0 33
N1 31
AJCC 7th edition
N0 33
N1 13
N2 9
N3 9
AJCC stage, 6th revision (n)
I 20
IIA 13
IIB 5
III 26
AJCC stage, 7th revision (n)
I 24
IIA 4
IIB 8
IIIA 12
IIIB 15
IIIC 1
AJCC, American Joint Committee on Cancer.
FIGURE 1. Kaplan-Meier plot of estimated overall survival for study co-
hort. Dotted lines denote 95% confidence band for probability of survival.
Median survivalwas 27months (lower 95% confidence interval, 22months).
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Patient Characteristics and Overall Survival Results
Esophagectomy for EAC was performed in 64 patients
(54 men and 10 women), with a median age of 68 years.
The histologic type was adenocarcinoma in all patients.
The patient characteristics are summarized in Table 1.
During follow-up, 30 patients were alive with a median
follow-up of 34 months (range, 2-76 months). The median
overall survival of the entire cohort was 27 months (lower
95% confidence interval [CI], 22 months). The estimated
probability of 3-year overall survival for the entire cohort
was 49% (95% CI, 38%-64%; Figure 1).
Gene Identification and Analysis of Gene Expression
Signatures
Gene expression was successfully assessed in the
samples from all 64 patients with EAC. Adequate tumorThe Journal of Thoracic and Carepresentation in the specimen was ascertained before analy-
sis,with amedian tumor percentageof 80%.After filtering all
54,647AffymetrixU133probe sets, 40,855probe setswith an
associated gene symbol were selected. These were filtered to
remove the probe sets with low variance, leaving 10,214
probe sets for survival analysis. Multiple probe sets mapping
to the same gene were then averaged, yielding 7425 unique
gene symbols. The tail-strength statistic for these genes was
0.318 (95% CI, 0.301-0.333), indicating a significant associ-
ation of the data set as a whole with overall survival. We con-
ducted semisupervised classification of the patients as
follows. First, we calculated the principal component Wald
scores for each gene. Next, we used cross-validation to step
through a series of increasingly stringent thresholds to select
a number of genes that appeared optimal. Choosing a thresh-
old Wald score of 2.0 produced a list of 59 genes.Survival and Stratification by Gene Expression
Signature
Hierarchical clustering of patients and genes. We ap-
plied unsupervised hierarchical clustering with 59 genes,
used to construct the risk classifier, and initially divided the
64-patient cohort into 2 clusters. That analysis (Figure 2)
showed 2 well-differentiated patient clusters, identified as
groupsA andB. This grouping successfully stratified patients
into low-risk (group A) and high-risk (group B) gene expres-
sion signatures groups for survival (Figure 3).
Classification and prediction of survival by gene expres-
sion signature. Using 3 principal components for the 59
genes, a risk score was calculated for each patient and
divided at the median to classify the patients into 2
risk groups. The Kaplan-Meier plots of these groups
(Figure 4, A) demonstrated successful classification
(P ¼ 7 3 108). Among the 32 patients identified as ‘‘low-
risk,’’ only 7 deaths were observed. In contrast, 27 of the 32rdiovascular Surgery c Volume 145, Number 2 507
FIGURE 2. Hierarchical clustering of 59 genes selected for classification. Hierarchical clustering of gene expression data with patients in columns and
genes in rows. The 59 genes selected for classification are labeled with their gene symbols. The heat map shows actual gene expression on the log 2 scale.
Clustering determined by Euclidean distance of logged expression data. Column dendrogram shows patient risk groups: group A (low risk; n¼ 25 patients)
and group B (high-risk; n ¼ 39 patients).
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high-risk gene expression signature group was 19 months
(95% CI, 10-25 months) and was not reached in the low-
risk gene expression signature group. The estimated 3-year
overall survival was 79% (95% CI, 65%-96%) in patients
with the low-risk gene expression signature and 21% (95%
CI, 10%-42%) in those with the high-risk gene expression
signature. To assess the level of optimism in this estimate,
we conducted a rigorous cross-validation, inwhich one subset
of thedatawasused forfittingamodel anda different subset of
patients (who were excluded from the model construction)
was used to test the model. We repeated this 10-fold cross-
validation 100 times. The resulting log-rank test was still
significant (P ¼ .0005; Figure 4, B). The cross-validated
high-risk gene expression signature group had a significantly
different overall survival than the groupwith the low-risk sig-
nature (Figure 4,B).Of the25T1 tumors studied, 8 (32%) had
a high-risk gene expression signature associated with a worse
prognosis. Similarly, 5 of31 (16%) node-positive patients had508 The Journal of Thoracic and Cardiovascular Surga low-risk gene expression signature, and 6 of 33 (18%) node-
negative patients had a high-risk gene expression signature.
Univariate and Multivariate Analysis of Clinical and
Pathologic Factors and Gene Expression Signature
The gene signature risk classification was tested for sig-
nificant associations in a multivariate proportional hazards
model that included the pathologic T and N stage. All path-
ologic factors, as defined in the AJCC Cancer Staging Man-
ual, 7th edition, when considered individually, including
increasing T and N stage (positive lymph nodes), were
associated with increased risk. The hazard ratio (HR) for in-
creasing T stage was 4.73 (95% CI, 2.24-9.99) and the HR
for number of positive lymph nodes (0-3 positive nodes)
was 1.57 (95%CI, 1.29-1.90). These results are summarized
in Table 2. A total of 21 patients (all with nodal disease) re-
ceived adjuvant chemotherapy. Owing to the selection of
patients with node-positive disease, adjuvant chemotherapy
was associated with a nonsignificant trend toward worseery c February 2013
FIGURE 3. Kaplan-Meier plot of estimated overall survival stratified by
gene expression profile, identified by unsupervised hierarchical clustering
in Figure 2. Group A had markedly better survival than group B, corre-
sponding to low- and high-risk gene expression profiles, respectively.
The log-rank test was significant (P<.0001).
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gene expression risk category defined by the 59-gene,
cross-validated risk score was strongly associated with sur-
vival, with a HR for the high- versus low-risk group of 3.46
(95%CI, 1.64-7.29; Table 2). To assess the independence of
the 59-gene signature, we adjusted the 59-gene signature
risk score for the following pathologic covariates: T stage,
number of positive lymph nodes (which uniquely deter-
mines the N stage), and tumor grade. A multivariate model
of the risk group after adjusting for both T and N stage
showed that the gene expression signature risk groupwas in-
dependently associated with survival. The adjusted HR for
the high-risk gene signature group was significant, with an
HR of 2.22 (95% CI, 1.02-4.03; P ¼ .04; Table 2 and
Figure 5).FIGURE 4. Classification of patients with supervised principle components a
each patient according to their expression of the 59 genes. The risk score was
patient cohorts (P<.0001). B, Same classification, using average of 100, 10-fo
The Journal of Thoracic and CaDISCUSSION
In the present prospective study of patients with EAC
treated with esophagectomy, we identified a preliminary,
59-gene classifier that stratified patients into high-risk and
low-risk prognostic categories. This internally cross-
validated prognostic signature was predictive of the out-
come in patients undergoing resection for EAC. According
to the HR and corresponding P value on multivariate anal-
ysis, this prognostic gene signature was a strong predictor of
outcome and was independent of the T and N stage.
An analysis of the pathways associated with this gene sig-
nature showed that the networks involved included those re-
sponsible for cell differentiation, cell proliferation, cellular
assembly and reorganization, and those involving cell death
and inflammatory responses. Inflammatory pathway genes
that were significantly associated included tumor necrosis
factor-a–inducedprotein 6,which is known to have an impor-
tant role in the protease network, and intercellular adhesion
molecule-1, which might play a role in tumor growth.A1-A3
The upregulation of inflammatory pathways has also been
demonstrated previously in esophageal cancer.A4 One of the
significantly associated cell cycle genes included cyclin-
dependent kinase inhibitor 2A, which encodes p16, and acts
through interaction with cyclin dependent kinase-4.A5,A6
Differential gene expression and microRNA patterns
among normal esophagus, BE, and cancer have been inves-
tigated15-18,23; however, the prognostic value of gene
expression profiles in esophageal cancer has not been
frequently studied. In one study, Hao and colleagues18 eval-
uated the gene expression patterns in 17 patients with BE or
EAC and compared thesewith those from the normal esoph-
agus and duodenum. They found that stromal gene expres-
sion was shared between BE and EAC but not with the
normal esophagus or duodenum. They emphasized the pos-
sible role of the stroma and extracellular matrix in thenalysis. Three principal components were used to estimate a risk score for
divided into 2 groups at the median. A, Comparison of low- and high-risk
ld cross-validations to derive the risk score (P ¼ .0005).
rdiovascular Surgery c Volume 145, Number 2 509
TABLE 2. Proportional hazards for overall survival: individual and joint covariate effects
Covariate Reference
Individual covariate effects Joint covariate effects
HR 95% CI P value HR 95% CI P value
59-Gene signature High vs low risk* 3.46 1.64-7.29 .0011 2.22 1.02-4.03 .0438
T stage 3-4a vs 1-2 4.73 2.24-9.99 < .0001 2.95 1.30-6.72 .0099
Positive LNs (n) 3 vs 0 1.57 1.29-1.90 .0019 1.33 1.06-1.67 .0139
HR, Hazard ratio; CI, confidence interval; LNs, lymph nodes. *Defined by splitting cross-validated risk score at the median.
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Sdevelopment of esophageal cancer.18 In another interesting
study comparing BE and EAC, Dahlberg and colleagues16
evaluated gene expression in 10 samples of EAC and iden-
tified genes that were differentially expressed compared
with normal controls. Selaru and colleagues17 compared 6
samples of EAC with 7 samples of BE and identified differ-
ential gene clusters in the cancer samples. Similarly, Green-
awalt and coworkers15 identified differentially expressed
genes when comparing BE and EAC. These studies did
not, however, evaluate the outcomes associated with the dif-
ferential gene expression in esophageal cancer. Tamoto and
colleagues14 analyzed the gene expression profile in pa-
tients with esophageal squamous cell carcinoma and identi-
fied genes that correlated with tumor stage, although the
outcomes were not specifically studied.
Gene expression profiles that classify patients into high-
and low-risk groups have been identified in other malignan-
cies, such as lung, breast, and head and neck cancer.10-13,24
However, few studies have evaluated the prognostic
implications of gene expression in esophageal cancer. In
addition to profiling gene expression, micro-RNA expression
could also add to the prediction of outcomes.A4 HammoudFIGURE 5. Multivariate analysis. Red vertical line depicts hazard ratio of
1, indicating no effect. All factors remained significant at P<.05. Hazard
ratio for gene signature, adjusting for T stage and N stage, was 2.2.
510 The Journal of Thoracic and Cardiovascular Surgand colleagues,19 in a very interesting study, evaluated gene
expression in patients with EAC. They evaluated 502 genes,
using a cDNA-mediated annealing, selection, extension,
and ligation assay in a retrospective study of paraffin-
embedded tissue. With a median follow-up of 25 months,
they found differential gene expression that correlated with
progression and survival. Although their study was unique
in many respects, its limitations included its retrospective na-
ture, evaluation of a relatively limited number of genes com-
pared with the DNA microarray technique, and the finding
that in their data set, known predictors, such as T stage and
lymph node status, did not correlate with the outcome. De-
spite these limitations, their study is one of the first to evaluate
gene expression profiles in esophageal cancer. In another
study of gene expression in EAC, 4 genes, verified by immu-
nohistochemistry, demonstrated an association with survi-
val.A7 Their study found that patients with all 4 of these
genes dysregulated had significantly worse survival.A7 In ad-
dition, integrated analysis of gene expression and compara-
tive genomic hybridization could reveal copy number
aberrations and genes with prognostic importance.A8
Implications and Future Directions
Molecular staging with evaluation of gene expression pro-
files in esophageal cancer has the potential to change treatment
paradigms. For example, although controversial, it is com-
monly stated that patientswith superficial tumors, in particular,
intramucosal tumors, can bemanaged by local endoscopic ex-
cision alone.3 However, in our series, a very interesting finding
was that approximately one third of the patients with superfi-
cial tumors (which included intramucosal cancer) had
a high-risk gene expression profile, indicating that for these
patients, the best care might be aggressive treatment.
Another interesting finding was that some patients had
node-positive disease but had a favorable prognostic signa-
ture. If these results are validated further, these patients might
potentially be spared aggressive, multimodality therapy. Fur-
thermore, gene expression profiles are being investigated to
predict the response to therapies.8,25 In a study evaluating
the correlation between gene expression and the response to
treatment (chemoradiotherapy), a prediction profile was
obtained for squamous cell carcinoma but not for
adenocarcinoma.A9 In another study of patients who received
neoadjuvant chemoradiotherapy and resection, 2 genes dem-
onstrated significant association with survival.A10 In other in-
vestigations, differences were seen in expression profilingery c February 2013
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and those who did not respond to treatment,25,A11,A12
suggesting that expression profiling could be of some value
in distinguishing patients with differing responses to
neoadjuvant therapy. In another study, angiogenesis gene-
related polymorphisms were related to tumor recurrence.A13
Gene expression profiles of the primary tumor can pro-
vide useful information toward our understanding of the bi-
ologic behavior of the tumor and in the selection and
tailoring of therapy. The expression signatures have the po-
tential to significantly add to traditional clinical risk factors
in the prediction of outcomes.13 These findings, if validated,
could lead to future clinical trials based on the gene expres-
sion profiles of the primary tumor.
Strengths and Limitations
The strengths of the present study were its prospective na-
ture, its focus on adenocarcinoma, and the application of
a standardized protocol. In addition, we rigorously internally
cross-validated the gene expression signature,whichwas pre-
dictive of outcome, by selecting genes with a threshold Wald
score of 2.0 or greater. This method allowed some control for
false discovery but is not as conservative as a strict control for
a fixed false discovery rate. Since we were conducting cross-
validation of candidate genes, we wanted to initially include
a larger set of genes, some of which might be important but
that would have been missed with a strict P value criterion.
Furthermore, although other studies of squamous cell cancer
have been published, our study is one of the first prospective
studies to evaluate the gene expression profiles in EAC. Peri-
operativemortality can confound the accuracy and analysis of
model building using the molecular characteristics of the pri-
mary tumor. To exclude this confounding variable, we ex-
cluded all patients who died within 30 days of surgery.
Cancer-specific mortality might be more specific; however,
it is more difficult and less reliable to obtain during
follow-up. Therefore,weused overall survival as an endpoint,
similar to the endpoints used in the Worldwide Esophageal
CancerCollaboration group and theAmerican Joint Commit-
tee on Cancer esophageal staging system.A14-A16 Moreover,
the median follow-up of 34 months in our series is one of
the longest reported evaluating the prognostic implications
of gene expression in esophageal cancer.
Our study did have several limitations. Neoadjuvant ther-
apy affects gene expression and confounds the analysis; there-
fore, we excluded patients who received neoadjuvant therapy
from our study. Although this is a strength with regards to
a clear gene expression analysis, a selection bias of the pa-
tients analyzed in our studymight exist owing to the exclusion
of the patientswho receivedneoadjuvant therapy.Thepatients
enrolled in the present study, however, represented a broad
spectrum of patients with esophageal cancer, who underwent
resection. After ascertaining that each sample had adequate
tumor representation, we used the entire sample and did notThe Journal of Thoracic and Cause laser capture microscopy to dissect out the neoplastic
cells. Although laser capture microscopymore precisely cap-
tures the neoplastic cells, a disadvantage of this method is that
it ignores any stromal tissue, an important component of the
tumor.18 Analyzing the entire specimen has the advantage
of including the tumor, along with the stromal component,
which ismore representative of the invivo tumor environment
and also would be more practical in future clinical applica-
tions. It has been recognized that tumors can be multiclonal
and heterogeneous, and it is possible that, despite confirming
the presence of tumor on pathologic examination, all areas of
heterogeneous tumors were not adequately represented.
We also acknowledge that our risk groups, as defined by
the gene signature, were only strictly valid in our data set.
We recognize that predictive models that are evaluated in
the same data used to construct the models will be overly
‘‘optimistic’’ in the sense that they will seem better in the
original data than in an independent set of patients. In lieu
of having an independent data set, we undertook a rigorous
cross-validation. In this cross-validation, we used one subset
of the data for fitting amodel and a different subset of patients
(whowere excluded from themodel construction) for testing
themodel. This process, whichwas repeated (in our case 100
times), simulates the decrease in predictive ability in a new
data set and is thus appropriately conservative for claiming
what this signature can potentially accomplish when tested
with a completely independent patient cohort. Despite the
robust analysis, these results are preliminary. More work is
required, and is ongoing, to refine this signature and elucidate
the functional pathways that determine the survival out-
comes of patients with esophageal cancer. Finally, more rig-
orous validation in an independent or larger set of patients is
required to further refine and validate the signature.CONCLUSIONS
In the present prospective study of gene expression in EAC,
the gene expression profile was significantly associated with
overall survival after esophagectomy.Furthermore, individual
genes were successfully combined into a strongly predictive,
internally cross-validated, gene signature. On multivariate
analysis, this gene signature was independent of both tumor
(T) and nodal (N) status. This gene expression profile is pre-
liminary, and additional refinement and validation is needed.
If validated further, these results could help stratify and select
patients for appropriate treatment and direct clinical trials of
neoadjuvant and adjuvant therapies for esophageal cancer.
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Dr Chuong D. Hoang (Stanford, Calif). I have nothing to
disclose.
Dr Pennathur and his group present a timely study showing that
traditional diagnostic and prognostic factors erroneously stratify
some patients some of the time, and I think his group has taken
a step forward into the future direction of personalized cancer
care. To be relevant, however, molecular prediction has to provide
additional information, independent of traditional criteria or pro-
vide prognostic information within the subgroups defined by those
traditional criteria. In this context, I have the following 3 questions.
First, could you please clarify whether any patients in your
study received neoadjuvant chemoradiotherapy, and, if so, howery c February 2013
Pennathur et al General Thoracic Surgery
G
T
Swere you able to retrieve in all 69 resection specimens more than
70% tumor representation for subsequent array profiling? Is it not
surprising, here, that there were no pathologic complete re-
sponders in your prospective study?
Dr Pennathur. Thank you, Dr Hoang, for your kind comments.
The first question, patients who had neoadjuvant chemotherapy
or radiotherapy were excluded from the study because those have
an effect on gene expression. These patients are patients who were
not treated with neoadjuvant therapy.
Dr Hoang. Including the T3, T4 that you mentioned?
Dr Pennathur. Yes, including the patients who had T3 in the
final pathology analysis.
Dr Hoang. Question 2, the 2-dimensional heat map of your
gene classifier showed that there was imperfect representation of
some of the high-risk patients who were grouped into the low-
risk gene signature and vice versa. What was the specific error
rate in your prognostication? How did your gene classifier com-
parewith the old and now the newTNM staging systems for esoph-
ageal cancer? Furthermore, were you able to segregate by stage
how your classifier performed?
Dr Pennathur. Again, thank you for those questions.
The purpose of the heatmap classifier was to investigatewhether
any gene pattern existswith the potential to classify patient risk, and
the division into 2 groups (A and B) was based purely on the empir-
ical clustering of the patients. The specific error rate of classification
cannot be found in this context becausewe used survival as the end-
point—not class—and illustrated the classification accuracy, not
with an error rate but with survival differences between groups.
The gene risk signature was independent of the pathologic stage
of the prior system. Regarding the questions about the new staging
system, we have not yet actually compared this gene signaturewith
the new staging system.We do plan on performing an analysis with
the new staging system and will include this in the manuscript.
Dr Hoang.My final and third question is, by choosing a micro-
array-based prediction method, how do you plan to overcome
some of the inherent weaknesses in this technology that have lim-
ited its widespread application in daily clinical tests? This includes
that microarray tests are labor-intensive, time-consuming, and ex-
pensive, there are issues with reproducibility, and, usually, these
tests include many numbers of genes, making data handling im-
practical and cumbersome most of the time.
Dr Pennathur. I think that is a very relevant question. I think
these technologies are constantly evolving. As it stands, it is labor
intensive, and of course, the cost is a factor. We believe that over
time, as this technology evolves, the cost factor could be ad-
dressed, and anticipate that it will decrease. Also, ultimately I
think it is going to be a combination of molecular staging, clinical
staging, and known prognostic factors, which is going to help de-
termine the prognosis of the patient. I think if it really allows us to
choose a personalized treatment for a particular patient in terms of
the resection we are doing, in terms of the selection for multimo-
dality treatment for the individual patient that translates to im-
proved outcomes, then I think the efforts and costs are worth it,
but I agree that currently the costs are quite high, and as the tech-
nology improves, we think the cost will come down.
Dr Hoang. Thank you.
Dr Sandro Mattioli (Bologna, Italy). If I understood you, you
have demonstrated that your gene patterns do correspond to higherThe Journal of Thoracic and Castage tumors, which is good, but you are surely aware that some
tumors grow slowly and this would not help your aims. But the ma-
jor criticism is that you have put together apples and oranges, be-
cause you did not define the esophageal adenocarcinoma. Not all
esophageal adenocarcinomas are the same. Some stem from one
origin; some others stem from another origin. You did not show
how many of those cancers were associated with BE or not.
Thus, I think you are very far from your aiming point.
DrPennathur.Thankyou for your comments.With regard to your
second question, we presume that most of these cancers came from
BE; however, this was not done as a separate analysis. Our aim in
the current study was to investigate the gene expression profiles in
all patients with esophageal adenocarcinoma who underwent esoph-
agectomy with criteria as detailed in our inclusion/exclusion criteria,
andnot restrict this to specific stages or its specificorigin; sowe are on
target with the aims of the current study. We appreciate your com-
ments and will consider your suggestions for a future study. With re-
gard to your initial question and statement—regarding the pathologic
stage and gene expression—the gene classifier predicts risk in all
stages, for example, predicts high-risk T1 patients as well as low-
risk T3 patients. For example, even in the high-risk group, there
were a lot of superficial tumors—T1patients andT2patients, approx-
imately 50% of them in the high-risk group were T1 and T2 patients,
and roughly one third of T1 patients were in the high-risk group. So,
the high-risk gene signature was not exclusively seen in the higher
stage tumors. In fact, the gene risk signature was independent of the
pathologic stage in these patients. So, I think there is a gene signature
encoded early on that determines the survival in these patients.
Dr Keshavjee. I think that was the most important part of your
presentation, that high-risk group did represent some T1 and T2
and N0 patients, and that is unique.
Dr Thomas M. Egan (Chapel Hill, NC). You showed elevated
expression and reduced expression, but compared to what? Did
you have a control?
Dr Pennathur. That is a great question. We reviewed some of
the DNA microarray literature; our gene arrays had an implicit
control in the sense that arrays are normalized to the average array.
Differential expressions between groups are then relative but
because all arrays are normalized, comparisons are meaningful.
Recognizable gene differences are predicated on both fold changes
(ratios of differences) and low P values.
Dr Egan. But how can you identify those a priori? Was it based
on their survival?
Dr Pennathur.We use our model to predict each patient’s risk
of death and then use the median of estimated risk to divide them
into high-risk and low-risk groups.
Dr Egan. The other question is related to the potential for sam-
pling error. How did you know you were just getting tumor versus
tumor and underlying tissue?
Dr Pennathur. I think that is a great question. We made sure
that the pathologists, who were co-investigators, examined the tu-
mor to ensure there was more than 70% tumor representation, and
we believe the tumor tissue, along with the stromal tissue, has an
important bearing on how the tumor behaves. That is why we did
not use, for example, laser capture microscopy and we took the
gross tumor, which we believe is more representative.
Thank you for your comments. We thank the Association for the
opportunity to present this paper.rdiovascular Surgery c Volume 145, Number 2 513
